Optimizing HIV prevention portfolios targeting people who inject drugs using dynamic economic modeling

使用动态经济模型优化针对注射吸毒者的艾滋病毒预防组合

• 批准号: 10454336
• 负责人: Natasha Martin
• 金额: $ 59.52万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-08-07 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10454336
• 关键词: AIDS prevention; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Address; Affect; Area; California; Central Asia; Collaborations; Communicable Diseases; Communities; Complex; Country; Data; Data Sources; Disease Outbreaks; Drug usage; Eastern Europe; Economic Models; Economics; Epidemic; Far East; General Population; Goals; Government; HIV; HIV Infections; HIV Seropositivity; Harm Reduction; Heterogeneity; Imprisonment; Incidence; Injecting drug user; Institution; International; Interruption; Intervention; Link; Middle East; Modeling; Needles; New South Wales; Northern Africa; Online Systems; Opioid agonist; Pharmaceutical Preparations; Policies; Prevalence; Prevention; Prevention Research; Prevention strategy; Prisons; Recording of previous events; Research; Research Personnel; Risk; Risk Behaviors; Site; Source; Syringes; Universities; Validation; Vulnerable Populations; Work; antiretroviral therapy; base; condoms; cost effective; cost effective intervention; cost effectiveness; infection burden; insight; model development; models and simulation; novel; pre-exposure prophylaxis; prevent; preventive intervention; programs; response; stimulant use; syndemic; systematic review; transmission process; uptake; user-friendly

Project Summary/Abstract This proposal aims to optimize country and regional HIV prevention strategies by developing an epidemic economic model of HIV prevention among people who inject drugs (PWID) for 108 countries worldwide using newly available global systematic review data. PWID remain a key risk group for HIV transmission, comprising the majority of new HIV infections in Eastern Europe and Central Asia. Additionally, PWID are important drivers of HIV epidemics in the Middle East and North Africa, and South and South East Asia. Even in countries with generalized HIV epidemics, PWID frequently have an elevated burden of infection and poor access to prevention interventions, creating disparities which limit the ability to achieve the UNAIDS target to reduce HIV incidence by 90% by 2030. Governments lack guidance on the most effective and cost-effective intervention portfolio to prevent HIV among PWID. Newly available and on-going global systematic review data compiled by our team provides important new data to address this question. Our overarching aim is to optimize HIV prevention policymaking for PWID using dynamic economic modeling informed by multiple large data sources. This proposal incorporates model development, validation, and dissemination, through the following specific aims: 1) Develop an epidemic model to estimate the impact of HIV prevention portfolios among PWID for every country with available HIV prevalence data among PWID (108 countries worldwide), based on data from multiple large systematic reviews. 2) Estimate the budgetary impact and cost-effectiveness of the optimal package of interventions for achieving the UNAIDS HIV incidence target among PWID in each country. 3) Externally validate the model in 9 key countries with the highest numbers of HIV-positive PWID. 4) Develop a user-friendly and web-based multi-platform portal for dissemination of the epidemic economic model and associated data. Our team of epidemic modelers, systematic review experts, and drug policy researchers are uniquely poised to utilize these comprehensive new data to provide critical insight into how to tackle HIV epidemics among PWID globally. Our work will have significant impact, guiding policymakers to make informed decisions regarding preventing HIV among this vulnerable group. Our proposal addresses the Office of AIDS Research high priority area of “reducing the incidence of HIV/AIDS.”

项目总结/文摘

项目成果

Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England.

HepCATT 干预专科药物诊所的成本效益，以改善英格兰注射吸毒者的病例发现和 HCV 治疗参与。

• DOI: 10.1111/add.14978
• 发表时间: 2020
• 期刊: Addiction (Abingdon, England)
• 作者: Ward,Zoe;Reynolds,Rosie;Campbell,Linda;Martin,NatashaK;Harrison,Graham;Irving,William;Hickman,Matthew;Vickerman,Peter
• 通讯作者: Vickerman,Peter

The cost-effectiveness of case-finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK.

• DOI: 10.1111/jvh.13503
• 发表时间: 2021-06
• 期刊: JOURNAL OF VIRAL HEPATITIS
• 影响因子: 2.5
• 作者: Macgregor, Louis;Ward, Zoe;Martin, Natasha K.;Nicholls, Jane;Desai, Monica;Hickson, Ford;Weatherburn, Peter;Hickman, Matthew;Vickerman, Peter
• 通讯作者: Vickerman, Peter

Modelling the impact of HIV and HCV prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania.

• DOI: 10.1002/jia2.25817
• 发表时间: 2021-10
• 期刊: Journal of the International AIDS Society
• 影响因子: 6
• 作者: Fraser H;Stone J;Wisse E;Sambu V;Mfisi P;Duran IJ;Soriano MA;Walker JG;Makere N;Luhmann N;Kafura W;Nouvellet M;Ragi A;Mundia B;Vickerman P
• 通讯作者: Vickerman P